You are here

Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Boston, Massachusetts, 02114 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Advanced Breast Cancer (Parts 1 and 2), Advanced Pancreatic Cancer (Part 1), Advanced Colorectal Cancer (Part 1), Advanced Cholangiocarcinoma (Part 1), Advanced Glioblastoma Multiforme (Part 1)
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Part 1:

- Ages eligible for study: 18 years or older.

- Male and female.

- Confirmed pathologic diagnosis of advanced breast cancer or pancreatic cancer or
colorectal cancer or cholangiocarcinoma or glioblastoma not curable with available
therapies, for whom bosutinib plus capecitabine is a reasonable treatment option.

Part 2:

- Ages eligible for study: 18 years or older.

- Female.

- Confirmed pathologic diagnosis of locally advanced or metastatic breast cancer, or
loco-regional recurrent breast cancer that is not amenable to curative treatment with
surgery or radiotherapy.

- Documented ER+ and/or PgR+/erbB2- or ER-/PgR-/erbB2- tumor based upon recently
analyzed biopsy.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Part 1:

- Prior bosutinib, or any other prior Src inhibitor.

- Prior chemotherapy with capecitabine or 5-FU for the treatment of metastatic disease
is allowed unless patient stopped therapy for toxicity.

Part 2:

- Prior bosutinib, or any other prior Src inhibitor prior chemotherapy with capecitabine
or 5-FU for the treatment of metastatic disease.

- Prior chemotherapy with capecitabine or 5-FU for adjuvant chemotherapy within the past
12 months.

- erbB2+ breast cancer.

NCT00959946
Pfizer
Terminated
Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now